Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

May 9, 2023 0

Longeveron in the NEWS On May 9, 2023, Longeveron (LGVN) announced new long-term follow-up data from …

Why CureVac Stock Traded Up in a Bad Day Market

May 8, 2023 0

CureVac B.V. CureVac (CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) …

CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV

May 4, 2023 0

Gilead Sciences CHMP Adopted Positive Opinion for Hepcludex® Today, May 4, 2023, Gilead Sciences (GILD) acknowledged …

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

May 1, 2023 0

May 01, 2023 (GLOBE NEWSWIRE) –Today, Intellia Therapeutics (NTLA) released its 2023 Corporate Responsibility report. The …

ImmunoGen’s Obvious Recent Progress

April 28, 2023 0

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results On April 28, 2023, ImmunoGen (IMGN) reviewed …

Vertex Receives CHMP Positive Opinion for ORKAMBI in Children with Cystic Fibrosis Aged 1 – >2 Years

April 27, 2023 0

Vertex Pharmaceuticals ORKAMBI Receives Positive CHMP Opinion Today, April 27, Vertex Pharmaceuticals (VRTX) announced that the …

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

April 25, 2023 0

Atea Pharmaceuticals Receives Fast Track Designation for Bemnifosbuvir Atea Pharmaceuticals (AVIR) announced that the U.S. FDA …

Apellis Pharmaceuticals: Validation of 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy

April 21, 2023 0

Apellis Pharmaceuticals Validation for Pegcetacoplan Apellis Pharmaceuticals (APLS) announced the receival of validation of its marketing applications …

CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

April 21, 2023 0

Important News from CymaBay Therapeutics Primary Biliary Cholangitis Today, April 21, 2023, CymaBay Therapeutics (CBAY) announced that …

Important News from Novartis MS Product Kesimpta®

April 20, 2023 0

From Novartis on April 20, 2023 The ALITHIOS open-label extension study demonstrated that continuous treatment with …

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

April 19, 2023 0

News from Innoviva That We Consider Positively Impacting and Extremely Important Innoviva, Inc. (INVA) (Innoviva), announced …

Why the FDA Accepted to Review Merck’s KEYTRUDA (sBLA) for The Treatment of HER2 Negative Gastric Adenocarcinoma

April 14, 2023 0

Merck in the NEWS Merck (MRK) announced that the U.S. FDA has accepted for review a …

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

April 12, 2023 0

Sanofi Commercial Control of Beyfortus Against RSV In the morning, we promised to tell our readers …

Regenxbio Receives FDA Fast Track Designation for RGX-202 for the Treatment of Duchenne Muscular Dystrophy

April 11, 2023 0

Regenxbio in the NEWS Today, the U.S. FDA granted Fast Track designation for Regenxbio (RGNX) Gene therapy …

Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

April 3, 2023 0

Vertex Pharmaceuticals and CRISPR Therapeutics Completion of BLAs Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Longeveron has Encouraging Trial Results for Hypoplastic Left Heart Syndrome

Why CureVac Stock Traded Up in a Bad Day Market

CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

ImmunoGen’s Obvious Recent Progress

Vertex Receives CHMP Positive Opinion for ORKAMBI in Children with Cystic Fibrosis Aged 1 – >2 Years

Atea Pharmaceuticals: The U.S. FDA Granted Fast Track Designation to Bemnifosbuvir Oral Antiviral for COVID-19

Apellis Pharmaceuticals: Validation of 4 Marketing Applications for Pegcetacoplan for Geographic Atrophy

CymaBay Therapeutics: Results From Phase 3 Study of Seladelpar in Patients with PBC Published in Hepatology

Important News from Novartis MS Product Kesimpta®

Innoviva: The FDA Advisory Committee Unanimously Recommended Approval of Sulbactam-Durlobactam

Why the FDA Accepted to Review Merck’s KEYTRUDA (sBLA) for The Treatment of HER2 Negative Gastric Adenocarcinoma

Sanofi to Reach Full Commercial Control of the Antibody Beyfortus (nirsevimab) against RSV in the U.S.

Regenxbio Receives FDA Fast Track Designation for RGX-202 for the Treatment of Duchenne Muscular Dystrophy

Vertex and CRISPR Complete Submission of BLAs to the US FDA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

TG Therapeutics Announced Positive CHMP Opinion of BRIUMVI for Relapsing Forms of MS in Adults

New Study from Neuvivo’s NP001: First to Link Regulation of the Innate Immune System with Respiratory Function in ALS

The EU CHMP Agency Recommended Approval of TG Therapeutics Firm’s BRIUMVI™ for Relapsing Forms of MS in Adults

The U.S. FDA Accepted Checkpoint Therapeutics Biotech BLA for Cosibelimab

BrainStorm Cell Therapeutics: Another Clinical-Stage Small Firm’s Product for the Devastating Disease ALS